Capstan Therapeutics, Inc. raised $175M in a Series B financing led by RA Capital Management to advance in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles
Capstan Therapeutics, Inc. raised $175M in a Series B financing led by RA Capital Management to advance in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles
03/20/24, 11:19 AM
Location
san diegoMoney raised
$175 million
Industry
therapeutics
biotechnology
health care
Round Type
series b
Investors
Vida Ventures, Polaris Partners, Pfizer Ventures, Orbi Med, Novartis Venture Fund, Leaps By Bayer, Eli Lilly And Company, Bristol Myers Squibb, Alexandria Venture Investments, Sofinnova Investments, Perceptive Advisors, Mubadala Capital, Johnson & Johnson Innovation Jjdc, Forbion, Ra Capital Management
Capstan Therapeutics, Inc. announced the successful closing of a $175M oversubscribed Series B financing. The financing was led by RA Capital Management, with participation from new investors Forbion, Johnson & Johnson Innovation - JJDC, Mubadala Capital, Perceptive Advisors, and Sofinnova Investments, as well as existing investors Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly and Company, Leaps by Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, and Vida Ventures.
Company Info
Location
san diego, california, united states
Additional Info
Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP). The company's core platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders.